


# EXPRESSIVE Phase III Program Countries of MK-8527

Seventeen countries in total are hosting sites for Merck's Phase III program of the monthly PrEP pill, MK-8527. EXPRESSIVE-11 launched in August 2025; EXPRESSIVE-10 launched in November 2025.



## EXPRESSIVE-11

Approximately 4,390 participants

Sexually active cisgender men, MSM, transgender men and women, gender non-binary persons who could benefit from PrEP

[ClinicalTrials.gov Study Record](https://clinicaltrials.gov)

## EXPRESSIVE-10

Approximately 4,580 participants

Sexually active cisgender adolescent girls, young women, and women who could benefit from PrEP

[ClinicalTrials.gov Study Record](https://clinicaltrials.gov)